Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

(2021) Joseph Mikhael et al.   Blood Cancer Journal

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

(2021) Philippe Moreau et al.   LANCET

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

(2021) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

The Circular Life of Human CD38: From Basic Science to Clinics and Back

(2020) Alberto L. Horenstein et al.   MOLECULES

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells

(2020) Chen Zhu et al.   Frontiers in Immunology

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide

(2019) Philippe Moreau et al.   Blood Cancer Journal

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab

(2019) Thomas G. Martin et al.   Cells

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

(2019) Michel Attal et al.   LANCET

Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design

(2018) Paul G Richardson et al.   Future Oncology

Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche

(2017) Antonella Chillemi et al.   Frontiers in Immunology

Second primary malignancies in multiple myeloma: an overview and IMWG consensus

(2016) P. Musto et al.   ANNALS OF ONCOLOGY

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

(2016) M. A. Dimopoulos et al.   BLOOD

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide

(2015) H Jiang et al.   LEUKEMIA

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance

(2015) Bryan Oronsky et al.   NEOPLASIA

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

(2014) J. Deckert et al.   CLINICAL CANCER RESEARCH

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

(2013) Jesus San Miguel et al.   LANCET ONCOLOGY

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology

(2008) Fabio Malavasi et al.   PHYSIOLOGICAL REVIEWS